Ajinomoto AminoScience Introduces Peptide Synthesis, Manufacturing Service

Ajinomoto Aminoscience said that the new service is designed as a tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

AjiPhase enables the use of a single peptide synthesis methodology throughout therapeutic peptide development, negating the need to transition between solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) methodologies as peptide requirements increase.

The use of a single synthetic methodology eliminates the need for additional development time required in switching from solid to liquid phase methods and also removes the need to revalidate the impurity profile when transitioning synthetic methods.

Dwayne Allen, business manager of biotechnology at Ajinomoto AminoScience, said: “For scientists in pharmaceutical and biotechnology product development, AjiPhase™ gives the benefits of SPPS with its efficient removal of un-reacted reagents.

“Those in R&D and business development roles appreciate the cost advantage of larger scale synthesis, as it is not limited by starting material linked to a solid support. This greatly increases the commercial viability of peptides, gives companies access to higher-purity peptides and reduces development time.”

Jack Heaton, president of Ajinomoto AminoScience, said: “With the launch of AjiPhase, pharmaceutical and biotechnology companies of all sizes now have new resource for their peptide needs as well as a partner with experience in process development, QA/QC, analytical services and regulatory support.”